Epidemiology and Natural History of Hepatitis B

ABSTRACT

Hepatitis B virus (HBV) is a common viral pathogen that currently infects an estimated 4 million people worldwide, including 400 million who have chronic infection. Persons with chronic HBV infection are at a lifelong risk of developing hepatocellular carcinoma (HCC) or cirrhosis, or both. Many persons with HBV are unaware that they carry the infection, and, of those who are chronically infected, only a minority receives routine, scheduled follow-up to monitor their disease status. Persons from high-risk populations, especially immigrants from nations where hepatitis B is highly endemic, should be tested for HBV seromarkers and should be vaccinated if they are found to be negative. The natural history of chronic HBV is a dynamic one: patients can fluctuate between periods of active liver inflammation and periods of inactive disease. Disease progression is influenced by various factors, including viral genotype and specific mutations, demographic features, concurrent viral infections, and social and environmental factors. Recent data suggest that antiviral therapy can decrease the risk of liver decompensation and liver-related death and reduce the risk of HCC in selected individuals with active liver disease and severe fibrosis. Persons identified with chronic HBV infection need lifelong, regular monitoring for the development of active liver disease and HCC.

KEYWORDS

Hepatitis B virus - natural history - management - epidemiology

REFERENCES

• 1 Lee W. Hepatitis B virus infection.  N Engl J Med. 1997;  337 1733-1745
• 2 Beasley R P. Hepatitis B virus: the major etiology of hepatocellular carcinoma.  Cancer. 1988;  61 1942-1956
• 3 McMahon B J. Hepatocellular carcinoma and viral hepatitis. In: Wilson RA Viral Hepatitis New York; Marcel Dekker 1997: 315-330
• 4 McMahon B J, Holck P, Bulkow L, Snowball M M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus.  Ann Intern Med. 2001;  135 759-768
• 5 McQuillan G M, Townsend T R, Fields H A, Carrol M, Leahy M, Polk B F. Seroepidemiology of hepatitis B virus infection in the United States.  Am J Med. 1989;  87(suppl 3A) 5S-10S
• 6 CDC .Hepatitis B virus: a comprehensive strategy for limiting transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep. 1991 40 RR-13 1-25
• 7 Beasley R P, Hwang L Y, Lee G C et al.. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.  Lancet. 1983;  322 1099-1102
• 8 Bond W W, Favero M S, Petersen N J, Gravelle C R, Ebert J W, Maynard J E. Survival of hepatitis B virus after drying and storage for one week [letter].  Lancet. 1981;  1 550-551
• 9 Petersen N J, Barrett D H, Bond W W et al.. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages.  Appl Environ Microbiol. 1976;  32 572-574
• 10 Beasley R P, Hwang L Y, Lin C C et al.. Incidence of hepatitis B virus in preschool children in Taiwan.  J Infect Dis. 1982;  146 198-204
• 11 Corsaget P, Yvonnet B, Chotard J et al.. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal).  J Med Virol. 1987;  22 1-5
• 12 McMahon B J, Alward W LM, Hall D B et al.. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.  J Infect Dis. 1985;  151 599-603
• 13 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B 2000. Summary of a workshop.  Gastroenterology. 2001;  120 1828-1853
• 14 McMahon B J. Chronic carriers of hepatitis B virus who clear hepatitis B surface antigen: Are they really “off the hook”?.  Hepatology. 1998;  28 265-267
• 15 Wai C T, Fontana R J. Clinical significance of hepatitis B virus genotypes, variants, and mutants.  Clin Liver Dis. 2004;  8 321-352
• 16 Lok A SF, McMahon B J. American Association for the Study of Liver Disease Practice Guideline: chronic hepatitis B.  Hepatology. 2001;  34 1225-1241
• 17 Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes.  Intervirology. 2003;  46 329-338
• 18 Chu C J, Keeffe E B, Han S H et al.. Hepatitis B virus genotypes in the United States: results of a nationwide study.  Gastroenterology. 2003;  125 444-451
• 19 Kao J H, Chen P J, Lai M Y, Chen D S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.  Gastroenterology. 2003;  124 327-334
• 20 Chu C J, Keeffe E B, Han S Y et al.. Prevalence of HBV precore/core promoter variants in the United States.  Hepatology. 2003;  38 619-628
• 21 Hadziyannis S J. Hepatitis D.  Clin Liver Dis. 1999;  3 309-325
• 22 Liaw Y F, Sung J JY, Chow W C et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 1521-1531
• 23 Yang B, Zhang B, Xu Y et al.. Prospective study of early detection for primary liver cancer.  J Cancer Res Clin Oncol. 1997;  123 357-360
• 24 The EASL Jury . EASL International Consensus Conference on Hepatitis B 13-14 September, 2002, Geneva, Switzerland. Consensus statement (short version).  J Hepatol. 2003;  38 533-540
• 25 Liaw Y F, Leung N, Guan R, Lau G KK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update.  J Gastroenterol Hepatol. 2003;  18 239-245